Head-to-head · WeighScore
SexyMD vs WeightRx
The verdict
WeightRx takes it — 72.1/100 to 60.3/100.
WeightRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. WeightRx is a telehealth provider publishing compounded semaglutide at $250/mo and compounded tirzepatide at $83/mo.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | SexyMD | WeightRx |
|---|---|---|
| WeighScore | 60.3/100 | 72.1/100 |
| Grade | C | C |
| Site position | #369 | #94 |
| Semaglutide | $269/mo (four-week plan; the $199 in every headline is the 48-week rate) | $250/mo (compounded) |
| Tirzepatide | $369/mo (four-week plan; the $299 in every headline is the 48-week rate) | $83/mo (term not published, compounded) |
| Coverage | 47 states (all except Arkansas, Mississippi and New Jersey) | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #369 · C
Strengths
- Publishes an exact exclusion list — all states except Arkansas, Mississippi and New Jersey — rather than a nationwide claim
- States both compounding classes in the Terms, so the class question is answered even though the pharmacy is not named
- Names the prescribing entity and the professional corporation behind it
- Sells two microdose products with their own published price tables rather than only as a discount tier
Where it loses points
- Every headline price is the 48-week commitment rate: $199 against a month-to-month figure of $269, and $299 against $369, with an asterisk that resolves to no footnote
- The same footer, on every page, says both that the service is available in all 50 states and that it is available in all states except three
- The two microdose products publish identical prices for their 4-, 8- and 12-week plans, in the same table format that carries real tiers elsewhere
- The microdose page contradicts itself on dosing frequency inside a single page
- Three unsourced and mutually inconsistent social-proof figures appear across the homepage, the footer and the product pages
- The checkout claims two patient counts for a single day that together exceed the total the site's own badge claims
- No pharmacy is named, and what the price includes is never itemized on any product page
Site position #94 · C
Strengths
- The tirzepatide figure is published up front, and it is genuinely low against the field
- Both molecules are offered
- No membership charge is advertised alongside the medication rate
Where it loses points
- The $83 monthly rate is advertised as '$83/month ($997/year)', which is twelve months of it — no month-to-month rate is separately published, and the terms state that a rate is locked for its full term
- Both product pages linked from the homepage return 404, so the plan terms cannot be read before intake
- Six- and twelve-month plans are non-refundable, and eligible refunds carry a 5% processing fee
- No dose strength is published anywhere, so what the $83 buys is not stated
- The named operator is Twist G Marketing, LLC rather than a clinical entity, and the terms carry a binding arbitration and class-action waiver
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). CoreAge Rx advertises flat dose pricing for compounded injections, with no membership fee; its consultation-fee and refund deadlines deserve a close read before paying.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.